




RealRate

PHARMACEUTICAL 2022

Chinook Therapeutics INC
Rank 155 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Chinook Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chinook Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Chinook Therapeutics INC is the variable Assets, Current, reducing the Economic Capital Ratio by 8.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 69% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	300,639
Cost of Goods Sold	0
Intangible Assets	26,126
Liabilities, Current	40,085
Liabilities, Non-Current	39,589
Other Assets	218,103
Other Compr. Net Income	-66
Other Expenses	31,097
Other Liabilities	30,486
Other Net Income	5,421
Other Revenues	51,625
Property and Equipment	18,935
Research and Development	96,987
Selling, General and Administrative Expense	31,899

Output Variable	Value in 1000 USD
Assets	563,803
Liabilities	110,160
Expenses	159,983
Revenues	51,625
Stockholders Equity	453,643
Net Income	-102,937
Comprehensive Net Income	-102,970
BaseVar	445,529
ECR before Limited Liability	263%
Economic Capital Ratio	344%